Asterias Biotherapeutics Inc (NYSE:AST) Expected to Announce Quarterly Sales of $1.85 Million
Equities analysts predict that Asterias Biotherapeutics Inc (NYSE:AST) will report $1.85 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Asterias Biotherapeutics’ earnings. The highest sales estimate is $2.20 million and the lowest is $1.50 million. Asterias Biotherapeutics reported sales of $1.53 million during the same quarter last year, which would suggest a positive year over year growth rate of 20.9%. The business is scheduled to report its next quarterly earnings report on Monday, August 21st.
On average, analysts expect that Asterias Biotherapeutics will report full year sales of $1.85 million for the current fiscal year, with estimates ranging from $4.00 million to $8.90 million. For the next fiscal year, analysts anticipate that the firm will post sales of $5.25 million per share, with estimates ranging from $200,000.00 to $10.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Asterias Biotherapeutics.
AST has been the subject of a number of recent research reports. Laidlaw initiated coverage on Asterias Biotherapeutics in a research note on Tuesday, April 4th. They set a “buy” rating and a $12.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Asterias Biotherapeutics in a research note on Thursday, March 30th. Finally, Zacks Investment Research cut Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Monday, April 3rd.
COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/09/asterias-biotherapeutics-inc-nyseast-expected-to-announce-quarterly-sales-of-1-85-million.html.
Shares of Asterias Biotherapeutics (NYSE:AST) opened at 3.55 on Friday. Asterias Biotherapeutics has a 52-week low of $2.32 and a 52-week high of $5.80. The company has a 50-day moving average price of $3.34 and a 200-day moving average price of $3.68. The stock’s market capitalization is $174.88 million.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.